Advertisement

Topics

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

13:32 EST 27 Feb 2018 | OncLive

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Original Article: Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement